COMP <GO>
ENTG vs TMO // ALTMAN Z-SCORE & DEBT/EQUITY
Entegris Inc. (NASDAQ) VS. Thermo Fisher Scientific Inc (NYSE) • 15-METRIC TALLY: ENTG 4
— TMO 11
▲ ALTMAN Z-SCORE & DEBT/EQUITY LEADER: ENTG
LAST: $154.39 (-3.51%) • MKT CAP: $24.45B
balance-sheet
4.65
LAST: $697.00 (-1.72%) • MKT CAP: $262.22B
balance-sheet
4.50
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (ENTG VS. TMO)
EMERALD CELL = QUANTITATIVE EDGE
| INSTITUTIONAL METRIC | ENTG | TMO | SPREAD (A - B) | ADVANTAGE | DEDICATED URL |
|---|---|---|---|---|---|
| Gross Profit Margin | 44.40% | 41.00% | +3.40 | ENTG | /gross-margins <GO> |
| Return on Invested Capital (ROIC) | 4.70% | 9.30% | -4.60 | TMO | /roic <GO> |
| EV/EBITDA & P/E Valuation | 39.1x | 30.4x | +8.70 | TMO | /valuation <GO> |
| Free Cash Flow Yield | 1.62% | 2.40% | -0.78 | TMO | /fcf-yield <GO> |
| Operating Margin | 14.30% | 17.40% | -3.10 | TMO | /operating-margins <GO> |
| Net Profit Margin | 7.40% | 15.10% | -7.70 | TMO | /net-margins <GO> |
| Revenue Growth (YoY) | -1.40% | 3.90% | -5.30 | TMO | /revenue-growth <GO> |
| Dividend Yield & FCF Payout Safety | 0.25% | 0.24% | +0.01 | ENTG | /dividend-safety <GO> |
| Altman Z-Score & Debt/Equity ACTIVE | 4.65 | 4.50 | +0.15 | ENTG | /balance-sheet <GO> |
| Piotroski F-Score Quality | 7/9 | 8/9 | -1.00 | TMO | /piotroski-score <GO> |
| Options Implied Move & Put/Call Skew | 7.30% | 6.70% | +0.60 | TMO | /options-implied-move <GO> |
| RSI-14 & 200D SMA Momentum | 53.3 | 59.1 | -5.88 | TMO | /rsi-technicals <GO> |
| 10Y Yield & FRED Macro Beta | 1.12 | 0.94 | +0.18 | ENTG | /macro-sensitivity <GO> |
| Forward P/E Multiple | 96.5x | 36.3x | +60.20 | TMO | /forward-pe <GO> |
| Enterprise Scale & Market Cap | $24.45B | $262.22B | -$237.77B | TMO | /market-cap <GO> |
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
| FISCAL YEAR | ENTG REV | TMO REV | ENTG GROSS % | TMO GROSS % | ENTG FCF | TMO FCF |
|---|---|---|---|---|---|---|
| FY 2025 | $3.20B | $44.56B | 44.4% | 44.0% | $396.2M | $6.29B |
| FY 2024 | $3.24B | $42.88B | 45.9% | 44.0% | $316.1M | $7.27B |
| FY 2023 | $3.52B | $42.86B | 44.0% | 44.0% | $485.9M | $6.48B |
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
ENTG // BETA 1.12
TMO // BETA 0.94